2026. 10
Date： 2026.10.30 -
Caliway Biopharmaceuticals Clarifies Unauthorized Online Claims Regarding CBL-514
The Company has recently identified information on certain online platforms and third-party websites claiming to offer, supply, market, or sell products related to CBL-514, the Company's investigational drug candidate currently under development. Such information may create confusion among investors, healthcare professionals, and the general public. The Company therefore issues the following clarification:
CBL-514 remains an investigational drug candidate in clinical development and has not received marketing approval in any country or jurisdiction. It is not commercially available in any market. The Company has not authorized any third party to supply, distribute, market, or sell CBL-514, nor has it authorized any third party to act on its behalf or imply any affiliation, partnership, licensing, agency, distribution, or other relationship with the Company. Any claim regarding the availability or sale of CBL-514 is unauthorized and is not associated with the Company.
The Company is aware that certain websites, social media platforms, or other channels may use or reference the Company's name, materials, information related to CBL-514, or other Company content without authorization for promotional or commercial purposes. The Company will continue to monitor such activities, preserve relevant evidence, and reserves all rights to pursue available legal remedies.
The Company reminds investors and the general public that information published on the Company's official website and through its official announcements should be considered the authoritative source of information regarding the Company and CBL-514. Any information not officially released by the Company should be independently verified. The public is advised not to rely on, purchase, or use products from unauthorized or unverifiable sources in order to protect their interests and safety.
The Company hereby issues this statement to clarify the matter.
CBL-514 remains an investigational drug candidate in clinical development and has not received marketing approval in any country or jurisdiction. It is not commercially available in any market. The Company has not authorized any third party to supply, distribute, market, or sell CBL-514, nor has it authorized any third party to act on its behalf or imply any affiliation, partnership, licensing, agency, distribution, or other relationship with the Company. Any claim regarding the availability or sale of CBL-514 is unauthorized and is not associated with the Company.
The Company is aware that certain websites, social media platforms, or other channels may use or reference the Company's name, materials, information related to CBL-514, or other Company content without authorization for promotional or commercial purposes. The Company will continue to monitor such activities, preserve relevant evidence, and reserves all rights to pursue available legal remedies.
The Company reminds investors and the general public that information published on the Company's official website and through its official announcements should be considered the authoritative source of information regarding the Company and CBL-514. Any information not officially released by the Company should be independently verified. The public is advised not to rely on, purchase, or use products from unauthorized or unverifiable sources in order to protect their interests and safety.
The Company hereby issues this statement to clarify the matter.